参考文献/References:
[1] Holst JJ.The incretin system in healthy humans:the role of GIP and GLP-1 [J].Metabolism,2019,96:46-55.DOI:10.1016/j.metabol.2019.04.014.
[2] Regazzo D,Barbot M,Scaroni C,et al.The pathogenic role of the GIP/GLPR axis in human endocrine tumors:emerging clinical mechanisms beyond diabetes [J].Rev Endocr Metab Disord,2020,21(1):165-183.DOI:10.1007/s11154-019-09536-6.
[3] Karpathakis A,Dibra H,Pipinikas C,et al.Prognostic impact of novel molecular subtypes of small intestinal neuroendocrine tumor [J].Clin Cancer Res,2016,22(1):250-258.DOI:10.1158/1078-0432.Ccr-15-0373.
[4] Regazzo D,Losa M,Albiger NM,et al.The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp(-)somatotropinomas [J].Eur J Endocrinol,2017,176(5):543-553.DOI:10.1530/eje-16-0831.
[5] Hage M,Chaligné R,Viengchareun S,et al.Hypermethylator phenotype and ectopic GIP receptor in GNAS mutation-negative somatotropinomas [J].J Clin Endocrinol Metab,2019,104(5):1777-1787.DOI:10.1210/jc.2018-01504.
[6] Van Eck NJ,Waltman L.Software survey:VOSviewer,a computer program for bibliometric mapping [J].Scientometrics,2010,84(2):523-538.DOI:10.1007/s11192-009-0146-3.
[7] Lecoq AL,Stratakis CA,Viengchareun S,et al.Adrenal GIPR expression and chromosome 19q13 microduplications in GIP-dependent cushing's syndrome [J].JCI Insight,2017,2(18):e92184. DOI:10.1172/jci.insight.92184.
[8] Chabre O,Liakos P,Vivier J,et al.Cushing's syndrome due to a gastric inhibitory polypeptide-dependent adrenal adenoma:insights into hormonal control of adrenocortical tumorigenesis [J].J Clin Endocrinol Metab,1998,83(9):3134-3143.DOI:10.1210/jcem.83.9.5140.
[9] Fujii H,Tamamori-Adachi M,Uchida K,et al.Marked cortisol production by intracrine ACTH in GIP-treated cultured adrenal cells in which the GIP receptor was exogenously introduced [J].PLoS One,2014,9(10):e110543.DOI:10.1371/journal.pone.0110543.
[10] Mazzuco TL,Chabre O,Sturm N,et al.Ectopic expression of the gastric inhibitory polypeptide receptor gene is a sufficient genetic event to induce benign adrenocortical tumor in a xenotransplantation model [J].Endocrinology,2006,147(2):782-790.DOI:10.1210/en.2005-0921.
[11] Mazzuco TL,Chabre O,Feige JJ,et al.Aberrant GPCR expression is a sufficient genetic event to trigger adrenocortical tumorigenesis [J].Mol Cell Endocrinol,2007,265-266:23-28.DOI:10.1016/j.mce.2006.12.034.
[12] Occhi G,Losa M,Albiger N,et al.The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone(GH)-promoter activity in GH3 cells [J].J Neuroendocrinol,2011,23(7):641-649.DOI:10.1111/j.1365-2826.2011.02155.x.
[13] Scaroni C,Albiger N,Daniele A,et al.Paradoxical GH increase during OGTT is associated with first-generation somatostatin analog responsiveness in acromegaly [J].J Clin Endocrinol Metab,2018,104(3):856-862.DOI:10.1210/jc.2018-01360.
[14] Rindi G,Wiedenmann B.Neuroendocrine neoplasia of the gastrointestinal tract revisited:towards precision medicine [J].Nat Rev Endocrinol,2020,16(10):590-607.DOI:10.1038/s41574-020-0391-3.
[15] Sherman SK,Maxwell JE,Carr JC,et al.GIPR expression in gastric and duodenal neuroendocrine tumors [J].J Surg Res,2014,190(2):587-593.DOI:10.1016/j.jss.2014.01.044.
[16] Waser B,Rehmann R,Sanchez C,et al.Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors [J].J Clin Endocrinol Metab,2012,97(2):482-488.DOI:10.1210/jc.2011-2454.
[17] Waser B,Beetschen K,Pellegata NS,et al.Incretin receptors in non-neoplastic and neoplastic thyroid c cells in rodents and humans:relevance for incretin-based diabetes therapy [J].Neuroendocrinology,2011,94(4):291-301.DOI:10.1159/000330447.
[18] Sherman SK,Carr JC,Wang D,et al.Gastric inhibitory polypeptide receptor(GIPR)is a promising target for imaging and therapy in neuroendocrine tumors [J].Surgery,2013,154(6):1206-1213.DOI:10.1016/j.surg.2013.04.052.
[19] Körner M,Waser B,Reubi JC.Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors? [J].Neuroendocrinology,2015,101(1):45-57.DOI:10.1159/000371804.
[20] Gourni E,Waser B,Clerc P,et al.The glucose-dependent insulinotropic polypeptide receptor:a novel target for neuroendocrine tumor imaging—first preclinical studies [J].J Nucl Med,2014,55(6):976-982.DOI:10.2967/jnumed.113.133744.
[21] Reubi JC,Waser B.Triple-peptide receptor targeting in vitro allows detection of all tested gut and bronchial NETs [J].J Nucl Med,2015,56(4):613-615.DOI:10.2967/jnumed.114.153189.
[22] Eriksson O,Velikyan I,Haack T,et al.Drug occupancy assessment at the glucose-dependent insulinotropic polypeptide receptor by positron emission tomography [J].Diabetes,2021,70(4):842-853.DOI:10.2337/db20-1096.